Search Results
Sep 07, 2026, 09:00 ET CART Blood Pressure Monitor Demonstrates Utility in BP Monitoring for AF and Heart Failure Patients
limitations with conventional cuffs due to irregular pulses or high variability.Other clinical achievements were also highlighted. Professor Hae-Young Lee (Seoul National University Hospital) reaffirmed the CART blood pressure monitor's high reliability by fulfilling European Society of Hypertension
More news about: Sky Labs
Sep 07, 2026, 03:00 ET CART Blood Pressure Monitor Demonstrates Utility in BP Monitoring for AF and Heart Failure Patients
limitations with conventional cuffs due to irregular pulses or high variability.Other clinical achievements were also highlighted. Professor Hae-Young Lee (Seoul National University Hospital) reaffirmed the CART blood pressure monitor's high reliability by fulfilling European Society of Hypertension
More news about: Sky Labs
Sep 07, 2026, 03:00 ET CART-Blutdruckmessgerät zeigt Nutzen bei der Blutdrucküberwachung von Patienten mit Vorhofflimmern und Herzinsuffizienz
Schwankungen bislang an ihre messtechnischen Grenzen stießen.Darüber hinaus wurden weitere klinische Studienergebnisse vorgestellt. Professor Hae-Young Lee (Seoul National University Hospital) bestätigte erneut die hohe Messgenauigkeit des CART-Geräts, das die Empfehlungen der European Society
More news about: Sky Labs
Sep 07, 2026, 03:00 ET El monitor de presión arterial CART demuestra su utilidad en la monitorización de la presión arterial en pacientes con fibrilación auricular e insuficiencia cardíaca
técnicas debido a pulsos irregulares o a una elevada variabilidad.Asimismo, se destacaron otros importantes resultados clínicos. El profesor Hae-Young Lee (Seoul National University Hospital) reafirmó la elevada precisión de las mediciones del monitor CART al cumplir con las recomendaciones de
More news about: Sky Labs
Sep 07, 2026, 03:00 ET Le tensiomètre CART démontre son utilité dans la surveillance de la pression artérielle chez les patients atteints de fibrillation auriculaire et d'insuffisance cardiaque
l'irrégularité du pouls ou de fortes fluctuations tensionnelles.D'autres résultats cliniques probants ont également été mis en avant. Le professeur Hae-Young Lee (Seoul National University Hospital) a réaffirmé la haute précision des mesures du tensiomètre CART, conforme aux recommandations de l'European
More news about: Sky Labs
Sep 04, 2026, 02:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026
Hereditary Angioedema (HAE)Hereditary angioedema (HAE) is a rare genetic condition that causes sudden and unpredictable swelling in different parts of the body. In severe cases, it can affect the throat and become life-threatening, with a mortality rate of up to 40% 1. HAE affects about
More news about: Argo Biopharmaceutical Co., Ltd
Aug 24, 2026, 08:00 ET AZENTA ANNOUNCES LEADERSHIP TRANSITION
to the Board of Azenta, he also currently serves as Chair of the Board of Repligen Corporation and as a director at Haemonetics Corporation (NYSE: HAE).He previously served as Chairman and CEO at Ortho-Clinical Diagnostics (now QuidelOrtho Corporation), Chairman, President and CEO of Millipore
More news about: Azenta
Aug 06, 2026, 06:00 ET Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
onlineBOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations
More news about: Haemonetics Corporation
Aug 03, 2026, 16:15 ET New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
BOSTON, Aug. 3, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced
More news about: Haemonetics Corporation
Jul 28, 2026, 16:15 ET Martin Madaus Elected to Haemonetics Board of Directors
BOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that Martin
More news about: Haemonetics Corporation
Jul 27, 2026, 09:00 ET CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
for publication in a peer-reviewed journal.About Hereditary Angioedema (HAE) HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1 esterase inhibitor (C1INH), a protein
More news about: CSL
Jul 08, 2026, 16:05 ET Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company
More news about: Haemonetics Corporation
Jun 08, 2026, 08:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
Hereditary Angioedema (HAE)Hereditary angioedema (HAE) is a rare genetic condition that causes sudden and unpredictable swelling in different parts of the body. In severe cases, it can affect the throat and become life-threatening, with a mortality rate of up to 40% 1. HAE affects about
More news about: Argo Biopharmaceutical Co., Ltd
Jun 05, 2026, 06:30 ET Haemonetics Updates Financial Reporting Segments
BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its
More news about: Haemonetics Corporation
Jun 02, 2026, 16:05 ET Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference
More news about: Haemonetics Corporation
May 27, 2026, 12:00 ET Highland Arms Enterprises Acquires Precision Garage Door Service of Portland and Willamette Valley
WOODINVILLE, Wash., May 27, 2026 /PRNewswire/ -- Highland Arms Enterprises (HAE), a partner company of Main Post Partners and one of the largest franchisee operators within both the Precision Garage Door Service and Neighborly® systems,
More news about: Highland Arms Enterprises LLC DBA Precision Garage Door Service
May 13, 2026, 14:14 ET Angioedema hereditário: uma iniciativa europeia para dar visibilidade a uma doença ainda pouco conhecida
de maio de 2026 /PRNewswire/ -- Para assinalar o Dia Mundial da HAE a 16 de maio, a BioCryst Ireland, uma empresa da Neopharmed Gentili, anuncia hoje uma nova iniciativa para sensibilizar para o angioedema hereditário (HAE), uma doença genética rara que afeta aproximadamente 1 em cada
More news about: BioCryst Ireland, a Neopharmed Gentili company
May 13, 2026, 09:41 ET Dziedziczny obrzęk naczynioruchowy: europejska inicjatywa na rzecz zwrócenia uwagi na to mało znane schorzenie
W ramach Światowego Dnia HAE, który przypada na 16 maja, BioCryst Ireland, spółka należąca do Neopharmed Gentili, ogłosiła dzisiaj realizację inicjatywy na rzecz podnoszenia świadomości w zakresie dziedzicznego obrzęku naczynioruchowego (Hereditary Angioedema, HAE), rzadkiej choroby genetycznej
More news about: BioCryst Ireland, a Neopharmed Gentili company
May 13, 2026, 04:00 ET Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition
May 13, 2026 /PRNewswire/ -- To mark World HAE Day on May 16, BioCryst Ireland, a Neopharmed Gentili company, today announces a new initiative to raise awareness of Hereditary angioedema (HAE), a rare genetic disease affecting approximately 1 in 50,000 people[¹].
More news about: BioCryst Ireland, a Neopharmed Gentili company
May 07, 2026, 06:00 ET Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
onlineBOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations
More news about: Haemonetics Corporation
May 05, 2026, 06:00 ET Haemonetics to Present at Bank of America 2026 Healthcare Conference
BOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of America 2026 Healthcare Conference on
More news about: Haemonetics Corporation
Apr 24, 2026, 06:20 ET New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication
More news about: Haemonetics Corporation
Apr 01, 2026, 16:05 ET Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will
More news about: Haemonetics Corporation
Mar 30, 2026, 16:15 ET Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
technologiesBOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug
More news about: Haemonetics Corporation
Mar 24, 2026, 08:00 ET Argo Biopharma Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
data, entered Phase II and received Breakthrough Therapy Designation in China, supporting its potential as a functional cure. BW-20805 for patients with HAE progressed into Phase II with recent encouraging data and received Fast Track Designation from the U.S. FDA. In cardiovascular disease, we expanded our
More news about: Argo Biopharmaceutical Co., Ltd